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Introduction
Bone is the most common site for metastasis in breast cancer 
(BCa) (1). In about 20% of the patients, tumors of the 
breast metastasize to the bone. Moreover, bone metastasis 
(BM) occurs in more than half of the cases showing distant 
metastases (2). Additionally, up to 70% of the patients who 
succumb to BCa show evidence of metastatic bone disease, 
post-mortem (3). BCa patients with first BM have a median 
survival time of about 20 months, and a 10% 5-year survival 
rate (4). Whereas, the 5-year survival rate for BCa patients 
with singular or oligometastatic bone disease is in the 
favorable range of 58.4–83% (5-7).
The treatment of patients with BM includes the systemic 
administration of antitumor and antiresorptive agents, and/
or localized radiation therapy (RT), radiofrequency ablation, 
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and surgery. RT especially plays an important role due to the 
radiosensitivity of BCa cells (8). Pain, limited movements, 
risk of fracture, after surgical intervention, and spinal 
cord compression are the indications for palliative RT (9). 
While pain relief is generally observed within a few days after 
the start of RT, radiologically detectable recalcification and 
stabilization commence at the earliest within 6–12 weeks 
after termination of RT. Moreover, asymptomatic patients 
with favorable prognostic factors can be treated using RT (10). 
Furthermore, high-dose RT may provide long-term 
localized control from skeletal manifestations and improve 
the overall survival (OS) of patients with oligometastases.
Here, we have described RT for the treatment of patients 
with oligometastatic bone disease in other primary sites and 
in BCa, and the future perspectives.
RT for oligometastatic bone disease in other 
primary sites
Some studies have opted RT for oligometastatic bone 
disease in other primary sites (Table 1) (11-20), and 8 of 
these 10 studies have used stereotactic body radiation 
therapy (SBRT). Sixty-seven percent of Grade ≥3 toxicities 
were fractures requiring a surgery. Overall, they resulted in 
excellent outcomes with mild toxicities. 
A recent SABR-COMET randomized phase II study (21) 
has compared the responses to SBRT (30–60 Gy in 3–4 
fractions or 16–24 Gy in single fraction) and conventional 
RT (8 Gy in single fraction to 30 Gy in 10 fractions) in 99 
patients who had a controlled primary malignancy with 
1–5 metastatic lesions in mixed primary sites. Amongst 
these, about 33.5% account for metastases to the bone. The 
median OS in the conventional RT group was 28 months 
as compared to 41 months in the SBRT group (P=0.090; 
where P<0.20 designates a positive trial). Adverse events 
of grade 2 or worse occurred in 9% of conventional RT 
group compared to 29% in the SBRT group (P=0.026). 
Additionally, treatment-related deaths occurred in 4.5% 
cases in the SBRT group, while no deaths occurred in the 
conventional RT group.
Several studies recommend SBRT for treatment of 
oligometastatic bone disease (22-31).The American College 
of Radiology Appropriateness Criteria suggests that 
aggressive local therapy of oligometastatic spine disease 
may provide survival benefit to the patients, although 
additional data would be required to understand the role 
of highly conformal RT techniques that allow for radiation 
dose escalation (32). The evidence-based guidelines of The 
American Society for Radiation Oncology (ASTRO) do not 
describe the use of curative intent SBRT for treatment of 
Table 1 RT for oligometastatic bone disease in other primary sites
Author, year
No. of 
patients
Histology RT dose and fractionation
Local control 
outcomes
Survival 
outcomes
Grade ≥3 
toxicity
Patel et al. (11), 2019 51 Prostate 10 Gy ×3, SBRT 90% (3 years) 73% (4 years) 0
Silva et al. (12), 2019 20 Mixed 8–10 Gy ×3, 5–8 Gy ×5, 
SBRT
100% (1 year) NR 5%
Siva et al. (13), 2018 20 Prostate 20 Gy ×1, SBRT 89% (2 years) 100% (2 years) 3%
Hosaka et al. (14), 2016 27 Mixed 37.5–60 Gy 64.3% (4 years) 56.3% (4 years) NR
Ursino et al. (15), 2015 28 Mixed 24 Gy ×1, 9 Gy ×3, SBRT 69% (3 years) 71.7% (3 years) 2.5%
Owen et al. (16), 2014 74 Mixed 18 or 24 Gy ×1, 10 Gy ×3, 
SBRT
91.8% (1 year) 81.4% (1 year) 0
Thibault et al. (17), 2014 13 Renal cell 
cancer
18–24 Gy ×1, 10–12 Gy ×2, 
SBRT
61% (2 years) 73% (2 years) 6.6%
Muacevic et al. (18), 2014 40 Prostate 16.5–22 Gy ×1, SBRT 95.5% (2 years) * NR
Wowra et al. (19), 2008 102 Mixed 15–24 Gy ×1, SBRT 98% (1.25 years) 68% (1.25 years) 2.0%
Rades et al. (20), 2007 521 Mixed 8 Gy ×1, 3 Gy ×10,  
2 Gy ×20 
78% (3 years) 50% (3 years) 0
*, the 75% survival proportion was achieved at 17.5 months. RT, radiation therapy; SBRT, stereotactic body radiotherapy; NR, not 
reported. 
5098 Katayama et al. Radiotherapy for bone oligometastases in BCa
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2020;9(8):5096-5101 | http://dx.doi.org/10.21037/tcr.2020.01.35
oligometastatic bone disease (33). Instead, the guidelines 
suggest that eligible patients with metastases to the spine 
be considered for available SBRT trials to clarify the role of 
optimal treatment approach. 
RT for oligometastatic bone disease in BCa
Few studies suggest RT for treatment of patients with 
oligometastatic bone disease in BCa (Table 2) (5-7,19,34). In 
these studies, only a single patient presented grade 3 acute 
dermatitis with grade ≥3 toxicity. Overall, patients received 
a high radiation dose that resulted in favorable outcomes, 
and mild toxicities. Here, Milano et al. (5) reported that 
the 5- and 10-year OS rates after SBRT were 83% and 
75%, respectively, for bone-only patients vs. 31% and 17%, 
respectively, for other patients (P=0.002). Next, Rades 
et al. (20) suggest that the outcomes were most favorable in 
patients with myeloma/lymphoma followed by those with 
BCa, and that none of the BCa patients showed progression 
of motor deficits. Additionally, Yoo et al. (34) reported 
that high-dose RT (≥50 Gy10) and HER2-negative status 
were significantly associated with improved local control, 
and Takemoto et al. (7) reported that local recurrence was 
observed in a patient treated with 3 Gy ×10 irradiation, the 
lowest dose among the eleven patients.
In a prospective study by Owen et al. (16), 74 patients 
with non-spine bone oligometastases (inclusive of 8% BCa) 
treated with SBRT were administered 18 Gy or 24 Gy in a 
single fraction, or 30 Gy in 3 fractions. Of these, six patients 
with BCa did not present with local recurrence, although 
seven of 68 patients with other primary sites did. Also, the 
number of metastases at simulation (<5 vs. >5 metastases) 
was associated with reduced median OS post SBRT (10.8 
vs. 6.4 months; P<0.0001). Next, in a retrospective study by 
Kobayashi et al. (35), 35 of 75 patients with oligometastatic 
BCa (39% bone) were treated with systemic chemotherapy 
plus metastasis-directed surgery or RT, and 40 patients 
were treated with systemic chemotherapy only. The 10- 
and 20-year OS rates were 82% and 53%, respectively in 
patients with multidisciplinary treatments vs. 42% and 23%, 
respectively in patients treated with systemic therapy alone 
(P=0.0063). Jacobson et al. (36) analyzed the number of sites 
of initial involvement identified in radionuclide bone scans 
in relation to long-term outcome in 113 BCa patients with 
bone as the sole initial site of metastatic disease. Median 
survival from time of recurrence and time of original 
diagnosis for the three bone scan categories was one lesion 
(n=47), 53 and 86 months; two lesions (n=22), 38 and 
68 months; and ≥3 lesions (n=44), 22 and 58 months 
(P<0.0001 and P<0.005 for 1 and 2 lesions vs. ≥3).
Of note, none of the randomized clinical trials compares 
the effect of systemic chemotherapy plus RT with systemic 
chemotherapy alone for BCa patients with oligometastatic 
bone disease. However, the increased use of high-dose RT 
for treating oligometastatic bone disease, particularly in 
patients with BCa, as a “routine” option in many hospitals 
has made it difficult to conduct prospective randomized 
trials (37). The BCa expert panel of the German Society for 
Radiation Oncology and members of the Working Party 
of Gynecologic Oncology Breast Committee recommends 
a full dose-fractionated regimen, e.g., 2 Gy × 20–25 
cycles, for RT of BCa patients with oligometastatic bone 
disease (8). Accordingly, by combining the results of RT 
for oligometastatic bone disease in other primary sites, we 
recommend high-dose RT or SBRT for BCa patients with 
oligometastatic bone disease. 
Technically, the gross tumor volume (GTV) is the 
tumor visible in the magnetic resonance imaging (MRI) 
scans. In clinically suspected intradural extension, contrast-
enhanced MRI is recommended to delineate the meningeal 
Table 2 RT for oligometastatic bone disease in BCa
Author, year
No. of 
patients
RT dose and fractionation
Local control 
outcomes
Survival outcomes
Grade ≥3 
toxicity
Milano et al. (5), 2019 12 5 Gy ×10, SBRT 100% (5 years) 83% (5 years) 0
Miyata et al. (6), 2017 17 40–74 Gy, in 1.8–2 Gy fractions 85% (5 years) 73% (5 years) 5.9%
Yoo et al. (34), 2015 31 20–60 Gy 66.2% (5 years) 61.6% (5 years) NR
Takemoto et al. (7), 2009 11 2 Gy × (20–25), 3 Gy ×10 80% (5 years) 58.4% (5 years) NR
Rades et al. (20), 2007 149 8 Gy ×1, 3 Gy ×10, 2 Gy ×20 79% (3 years) 51% (3 years) 0
RT, radiation therapy; BCa, breast cancer; SBRT, stereotactic body radiotherapy; NR, not reported.
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enhancement and is included in the GTV. The clinical target 
volume (CTV) includes the GTV with an adequate (e.g., 
1–2 cm) margin. Of note, the CTV should always include 
the complete vertebral body in case of vertebral body 
involvement. In the case of unaffected compacta, extension 
of the CTV beyond the compacta is discouraged (8). 
The planning target volume (PTV) margin differs based 
on factors such as the use of image-guided radiotherapy 
(IGRT) or not, the method of IGRT, reproducibility, and 
respiratory motion. Furthermore, the three-dimensional 
(3D) treatment planning is essential, especially for lesions 
of the trunk, because the treatment of oligometastatic bone 
disease requires high-dose RT and checking the irradiated 
dose and volume of adjacent normal tissue. 
Future perspectives
Based on the current scenario, combined use of RT and 
immune checkpoint inhibitors (ICI) may enhance the antitumor 
immune response and produce a synergistic effect (38). 
The randomized double-blind international phase III 
PACIFIC trial (39) compared the effect of durvalumab as 
consolidation therapy with placebo in 713 patients with 
stage III locally advanced unresectable non-small cell lung 
cancer after treatment with platinum-based definitive 
chemoradiotherapy. The 24-month OS rate was 66.3% in 
the durvalumab group, as compared to 55.6% in the placebo 
group (two-sided P=0.005). Durvalumab significantly 
prolonged OS, as compared with placebo (stratified hazard 
ratio for death, 0.68; P=0.0025). Chicas-Sett et al. in their 
systematic review discussed the effect of combined RT and 
ipilimumab in patients with metastatic melanoma (40), 
where a survival benefit of eight months in favor of the RT 
plus ipilimumab combination was observed in comparison 
with the median OS of 11.4 months in the pooled analysis 
of phase II and III trials of ipilimumab without RT. 
Furthermore, there are several ongoing and completed 
clinical trials combining RT and ICI in metastatic BCa 
patients (41). In future, the combined use of RT and 
ICI may serve as a promising therapeutic option against 
oligometastatic bone disease in BCa.
Conclusions
Based on results from several studies, the overall survival 
of BCa patients with oligometastatic bone disease is 
favorable compared to those with metastatic bone disease. 
Furthermore, we recommend high-dose RT or SBRT 
for patients with oligometastatic bone disease. The use of 
MRI for proper target volume definition and 3D treatment 
planning especially for lesions of the trunk are essential for 
the treatment planning of RT. Finally, we anticipate that 
combinatorial treatment using RT and ICI may benefit BCa 
patients with oligometastatic bone disease.
Acknowledgments
Funding: None.
Footnote
Provenance and Peer Review: This article was commissioned 
by the Guest Editors (Tadahiko Shien and Kaori Terata) 
for the series “Loco regional therapy for metastatic breast 
cancer” published in Translational Cancer Research. The 
article was sent for external peer review organized by the 
Guest Editors and the editorial office.
Conflicts of Interest: All authors have completed the ICMJE 
uniform disclosure form (available at http://dx.doi.
org/10.21037/tcr.2020.01.35). The series “Loco-regional 
therapy for metastatic breast cancer” was commissioned by 
the editorial office without any funding or sponsorship. The 
authors have no other conflicts of interest to declare.
Ethical Statement: The authors are accountable for all 
aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are 
appropriately investigated and resolved.
Open Access Statement: This is an Open Access article 
distributed in accordance with the Creative Commons 
Attribution-NonCommercial-NoDerivs 4.0 International 
License (CC BY-NC-ND 4.0), which permits the non-
commercial replication and distribution of the article with 
the strict proviso that no changes or edits are made and the 
original work is properly cited (including links to both the 
formal publication through the relevant DOI and the license). 
See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
References
1. Fujino M, Suzuki K, Nishio M, et al. Strategy of radiation 
therapy for bone metastases and MSCC in breast cancer 
patients. Breast Cancer 2011;18:238-43. 
2. Coleman RE. Clinical features of metastatic bone 
5100 Katayama et al. Radiotherapy for bone oligometastases in BCa
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2020;9(8):5096-5101 | http://dx.doi.org/10.21037/tcr.2020.01.35
disease and risk of skeletal morbidity. Clin Cancer Res 
2006;12:6243s-9s.
3. Galasko C. The anatomy and pathways of skeletal 
metastases. In: Weiss L, Gilbert A (eds). Bone metastases. 
Boston: GK Hall, 1981:49-63.
4. Leto G. Current status and future directions in the 
treatment of bone metastases from breast cancer. Clin Exp 
Pharmacol Physiol 2019;46:968-71.
5. Milano MT, Katz AW, Zhang H, et al. Oligometastatic 
breast cancer treated with hypofractionated stereotactic 
radiotherapy: Some patients survive longer than a decade. 
Radiother Oncol 2019;131:45-51.
6. Miyata M, Ohguri T, Yahara K, et al. Salvage radiotherapy 
for solitary metachronous bone metastasis in patients with 
breast cancer. Anticancer Res 2017;37:2575-9.
7. Takemoto M, Niibe Y, Kaneyasu Y, et al. Radiation 
therapy for isolated osseous metastasis of breast cancer 
in perspective of oligo-recurrence. Jpn J Clin Radiol 
2009;54:516-9.
8. Souchon R, Feyer P, Thomssen C, et al. Clinical 
recommendations of DEGRO and AGO on preferred 
standard palliative radiotherapy of bone and cerebral 
metastases, metastatic spinal cord compression, and 
leptomeningeal carcinomatosis in breast cancer. Breast 
Care 2010;5:401-7. 
9. Souchon R, Wenz F, Sedlmayer F, et al. DEGRO practice 
guidelines for palliative radiotherapy of metastatic breast 
cancer: bone metastases and metastatic spinal cord 
compression (MSCC). Strahlenther Onkol 2009;185:417-24. 
10. Feyer PC, Steingraeber M. Radiotherapy of bone 
metastasis in breast cancer patients - Current approaches. 
Breast Care 2012;7:108-12. 
11. Patel PH, Chaw CL, Tree AC, et al. Stereotactic body 
radiotherapy for bone oligometastatic disease in prostate 
cancer. World J Urol 2019;37:2615-21. 
12. Silva SR, Gliniewicz A, Martin B, et al. Oligometastatic 
Disease State Is Associated with Improved Local Control 
in Patients Undergoing Three or Five Fraction Spine 
Stereotactic Body Radiotherapy. World Neurosurg 
2019;122:e342-8.
13. Siva S, Bressel M, Murphy DG, et al. Stereotactic 
Abative Body Radiotherapy (SABR) for Oligometastatic 
Prostate Cancer: A Prospective Clinical Trial. Eur Urol 
2018;74:455-62.
14. Hosaka S, Katagiri H, Honda Y, et al. Clinical outcome 
for patients of solitary bone only metastasis. J Orthop Sci 
2016;21:226-9.
15. Ursino S, Montrone S, Cantarella M, et al. Stereotactic 
body radiotherapy of bone metastases in oligometastatic 
disease: Prognostic factors of oncologic outcomes. Tumori 
2016;102:59-64. 
16. Owen D, Laack NN, Mayo CS, et al. Outcomes and 
toxicities of stereotactic body radiation therapy for 
non-spine bone oligometastases. Pract Radiat Oncol 
2014;4:e143-9. 
17. Thibault I, Al-Omair A, Masucci GL, et al. Spine 
stereotactic body radiotherapy for renal cell cancer spinal 
metastases: Analysis of outcomes and risk of vertebral 
compression fracture. J Neurosurg Spine 2014;21:711-8.
18. Muacevic A, Kufeld M, Rist C, et al. Safety and feasibility 
of image-guided robotic radiosurgery for patients with 
limited bone metastases of prostate cancer. Urol Oncol 
2013;31:455-60.
19. Wowra B, Zausinger S, Drexler C, et al. CyberKnife 
radiosurgery for malignant spinal tumors: characterization 
of well-suited patients. Spine 2008;33:2929-34.
20. Rades D, Veninga T, Stalpers LJA, et al. Outcome after 
radiotherapy alone for metastatic spinal cord compression in 
patients with oligometastases. J Clin Oncol 2007;25:50-6. 
21. Palma DA, Olson R, Harrow S, et al. Stereotactic 
ablative radiotherapy versus standard of care palliative 
treatment in patients with oligometastatic cancers (SABR-
COMET): a randomised, phase 2, open-label trial. Lancet 
2019;393:2051-8.
22. Shiloh R, Krishnan M. Radiation for Treatment of 
Painful Bone Metastases. Hematol Oncol Clin North Am 
2018;32:459-68.
23. Dunne EM, Fraser IM, Liu M. Stereotactic body radiation 
therapy for lung, spine and oligometastatic disease: 
current evidence and future directions. Ann Transl Med 
2018;6:283.
24. Kougioumtzopoulou A, Zygogianni A, Liakouli Z, et al. 
The role of radiotherapy in bone metastases: A critical 
review of current literature. Eur J Cancer Care (Engl) 
2017. doi: 10.1111/ecc.12724.
25. De Bari B, Alongi F, Mortellaro G, et al. Spinal metastases: 
Is stereotactic body radiation therapy supported by 
evidences? Crit Rev Oncol Hematol 2016;98:147-58.
26. Ahmed KA, Torres-Roca JF. Stereotactic body 
radiotherapy in the management of oligometastatic disease. 
Cancer Control 2016;23:21-9.
27. Taunk NK, Spratt DE, Bilsky M, et al. Spine radiosurgery 
in the management of renal cell carcinoma metastases. J 
Natl Compr Canc Netw 2015;13:801-9.
28. Gerszten PC. Spine metastases: from radiotherapy, 
surgery, to radiosurgery. Neurosurgery 2014;61 Suppl 
5101Translational Cancer Research, Vol 9, No 8 August 2020
© Translational Cancer Research. All rights reserved.   Transl Cancer Res 2020;9(8):5096-5101 | http://dx.doi.org/10.21037/tcr.2020.01.35
1:16-25.
29. Chan NK, Abdullah KG, Lubelski D, et al. Stereotactic 
radiosurgery for metastatic spine tumors. J Neurosurg Sci 
2014;58:37-44. 
30. Gerszten PC, Mendel E, Yamada Y. Radiotherapy and 
radiosurgery for metastatic spine disease: what are the 
options, indications, and outcomes? Spine 2009;34:S78-92.
31. Sahgal A, Larson DA, Chang EL. Stereotactic Body 
Radiosurgery for Spinal Metastases: A Critical Review. Int 
J Radiat Oncol Biol Phys 2008;71:652-65.
32. Lo SSM, Lutz ST, Chang EL, et al. ACR appropriateness 
criteria ® spinal bone metastases. J Palliat Med 
2013;16:9-19.
33. Lutz S, Balboni T, Jones J, et al. Palliative radiation therapy 
for bone metastases: Update of an ASTRO Evidence-Based 
Guideline. Pract Radiat Oncol 2017;7:4-12.
34. Yoo GS, Yu J Il, Park W, et al. Prognostic factors in 
breast cancer with extracranial oligometastases and the 
appropriate role of radiation therapy. Radiat Oncol J 
2015;33:301-9.
35. Kobayashi T, Ichiba T, Sakuyama T, et al. Possible clinical 
cure of metastatic breast cancer: Lessons from our 30-year 
experience with oligometastatic breast cancer patients and 
literature review. Breast Cancer 2012;19:218-37.
36. Jacobson AF, Shapiro CL, Van Den Abbeele AD, et 
al. Prognostic significance of the number of bone scan 
abnormalities at the time of initial bone metastatic 
recurrrence in breast carcinoma. Cancer 2001;91:17-24.
37. Ricardi U, Badellino S, Filippi AR. Clinical applications 
of stereotactic radiation therapy for oligometastatic 
cancer patients: A disease-oriented approach. J Radiat Res 
2016;57:i58-i68.
38. Iheagwara UK, Clump DA, Heron DE. 
Immunoradiosurgery: The convergence of SBRT and the 
immune response. In: Heron DE, Huq MS, Herman JM 
(eds). Stereotactic Radiosurgery and Stereotactic Body 
Radiation Therapy (SBRT). New York: Demos Medical 
Publishing, 2018:321-9.
39. Antonia SJ, Villegas A, Daniel D, et al. Overall survival 
with durvalumab after chemoradiotherapy in stage III 
NSCLC. N Engl J Med 2018;379:2342-50.
40. Chicas-Sett R, Morales-Orue I, Rodriguez-Abreu D, et al. 
Combining radiotherapy and ipilimumab induces clinically 
relevant radiation-induced abscopal effects in metastatic 
melanoma patients: A systematic review. Clin Transl Radiat 
Oncol 2017;9:5-11.
41. Hu ZI, Ho AY, McArthur HL. Combined Radiation Therapy 
and Immune Checkpoint Blockade Therapy for Breast 
Cancer. Int J Radiat Oncol Biol Phys 2017;99:153-64.
Cite this article as: Katayama N, Katsui K, Watanabe K, 
Nagao R, Otsuki K, Hiraki T, Kanazawa S. Radiation therapy 
for oligometastatic bone disease in breast cancer. Transl Cancer 
Res 2020;9(8):5096-5101. doi: 10.21037/tcr.2020.01.35
